Encompass Health Q3 revenue beats estimates, raises FY guidance

Encompass Health

29/10/2025 20:27

Overview

Encompass Health Q3 net operating revenue grows 9.4% yr/yr, beating analyst expectations, per LSEG data

Adjusted EPS for Q3 beats analyst expectations, reflecting strong operational performance

Company raises full-year 2025 guidance, indicating confidence in future growth

Outlook

Company raises full-year 2025 net operating revenue guidance to $5.905-$5.955 bln

Encompass Health updates 2025 adjusted EBITDA guidance to $1.235-$1.255 bln

Company revises 2025 adjusted EPS guidance to $5.22-$5.37

Result Drivers

EXPANSION - Opened three new hospitals, including first in Connecticut, and added 39 beds to existing hospitals, boosting capacity

DISCHARGE GROWTH - Increased patient discharges by 5%, with same-store discharge growth of 2.9%

RECOGNITION - Named America's Most Awarded Leader in Inpatient Rehabilitation by Newsweek and Statista for sixth consecutive year

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Operating Revenue
$1.47 bln
Q3 Adjusted EPS
Beat
$1.23
$1.20 (12 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Encompass Health Corp is $137.50, about 8.2% above its October 28 closing price of $126.28

The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 23 three months ago

Press Release: ID:nPn9f0YX9a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)